Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 437

1.

Activity of ceftolozane-tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered in Intensive Care Units in Spain: The SUPERIOR multicentre study.

García-Fernández S, García-Castillo M, Bou G, Calvo J, Cercenado E, Delgado M, Pitart C, Mulet X, Tormo N, Mendoza DL, Díaz-Regañón J, Cantón R; SUPERIOR Study Group.

Int J Antimicrob Agents. 2019 Feb 12. pii: S0924-8579(19)30027-5. doi: 10.1016/j.ijantimicag.2019.02.004. [Epub ahead of print]

PMID:
30769199
2.

Monitoring the antimicrobial susceptibility of Gram-negative organisms involved in intraabdominal and urinary tract infections recovered during the SMART study (Spain, 2016 and 2017).

Cantón R, Loza E, Aznar J, Castillo FJ, Cercenado E, Fraile-Ribot PA, González-Romo F, López-Hontangas JL, Rodríguez-Lozano J, Suárez-Barrenechea AI, Tubau F, Díaz-Regañón J, López-Mendoza D; SMART-Spain Working Group.

Rev Esp Quimioter. 2019 Feb 13. pii: canton13feb2019. [Epub ahead of print]

3.

Direct antimicrobial susceptibility testing from the blood culture pellet obtained for MALDI-TOF identification of Enterobacterales and Pseudomonas aeruginosa.

López-Pintor JM, Francisco CN, Sánchez-López J, García-Caballero A, de Bobadilla ELF, Morosini MI, Cantón R.

Eur J Clin Microbiol Infect Dis. 2019 Feb 2. doi: 10.1007/s10096-019-03498-y. [Epub ahead of print]

PMID:
30712228
4.

Simulating Multilevel Dynamics of Antimicrobial Resistance in a Membrane Computing Model.

Campos M, Capilla R, Naya F, Futami R, Coque T, Moya A, Fernandez-Lanza V, Cantón R, Sempere JM, Llorens C, Baquero F.

MBio. 2019 Jan 29;10(1). pii: e02460-18. doi: 10.1128/mBio.02460-18.

5.

Ozenoxacin: a review of preclinical and clinical efficacy.

Vila J, Hebert AA, Torrelo A, López Y, Tato M, García-Castillo M, Cantón R.

Expert Rev Anti Infect Ther. 2019 Jan 28:1-10. doi: 10.1080/14787210.2019.1573671. [Epub ahead of print]

PMID:
30686133
6.

Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae.

Abodakpi H, Chang KT, Gao S, Sánchez-Díaz AM, Cantón R, Tam VH.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01906-18. doi: 10.1128/AAC.01906-18. Print 2019 Feb.

PMID:
30530606
7.

From CLSI to EUCAST, a necessary step in Spanish laboratories.

Larrosa MN, Benito N, Cantón R, Canut A, Cercenado E, Fernández-Cuenca F, Guinea J, López-Navas A, Moreno MÁ, Oliver A, Martínez-Martínez L.

Enferm Infecc Microbiol Clin. 2018 Nov 5. pii: S0213-005X(18)30278-7. doi: 10.1016/j.eimc.2018.09.014. [Epub ahead of print] Review. English, Spanish.

PMID:
30409509
8.

Current approach to fosfomycin: From bench to bedside.

Candel FJ, Cantón R.

Enferm Infecc Microbiol Clin. 2019 Jan;37(1):1-3. doi: 10.1016/j.eimc.2018.10.002. Epub 2018 Oct 22. English, Spanish. No abstract available.

PMID:
30360920
9.

Prevalence, geographic risk factor, and development of a standardized protocol for fungal isolation in cystic fibrosis: Results from the international prospective study "MFIP".

Delhaes L, Touati K, Faure-Cognet O, Cornet M, Botterel F, Dannaoui E, Morio F, Le Pape P, Grenouillet F, Favennec L, Le Gal S, Nevez G, Duhamel A, Borman A, Saegeman V, Lagrou K, Gomez E, Carro ML, Canton R, Campana S, Buzina W, Chen S, Meyer W, Roilides E, Simitsopoulou M, Manso E, Cariani L, Biffi A, Fiscarelli E, Ricciotti G, Pihet M, Bouchara JP.

J Cyst Fibros. 2018 Oct 20. pii: S1569-1993(18)30839-7. doi: 10.1016/j.jcf.2018.10.001. [Epub ahead of print] No abstract available.

PMID:
30348610
10.

Early prosthetic endocarditis caused by Stenotrophomonas maltophilia.

Morte E, Tolmos M, Halperin A, Morosini MI, Cantón R, Hermida JM.

Med Mal Infect. 2018 Dec;48(8):543-546. doi: 10.1016/j.medmal.2018.09.004. Epub 2018 Oct 15. No abstract available.

PMID:
30336969
11.

Defining antimicrobial resistance in cystic fibrosis.

Kidd TJ, Canton R, Ekkelenkamp M, Johansen HK, Gilligan P, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Waters VJ; Antimicrobial Resistance in Cystic Fibrosis International Working Group.

J Cyst Fibros. 2018 Nov;17(6):696-704. doi: 10.1016/j.jcf.2018.08.014. Epub 2018 Sep 25. Review.

PMID:
30266518
12.

Emergence and dissemination of colistin-resistant Klebsiella pneumoniae isolates expressing OXA-48 plus CTX-M-15 in patients not previously treated with colistin in a Spanish university hospital.

Barragán-Prada H, Ruiz-Hueso P, Tedim AP, González-Candelas F, Galán JC, Cantón R, Morosini MI.

Diagn Microbiol Infect Dis. 2019 Feb;93(2):147-153. doi: 10.1016/j.diagmicrobio.2018.08.014. Epub 2018 Sep 8.

PMID:
30266401
13.

Antimicrobial susceptibility of non-fermenting Gram-negative pathogens isolated from cystic fibrosis patients.

Díez-Aguilar M, Ekkelenkamp M, Morosini MI, Merino I, de Dios Caballero J, Jones M, van Westreenen M, Tunney MM, Cantón R, Fluit AC.

Int J Antimicrob Agents. 2019 Jan;53(1):84-88. doi: 10.1016/j.ijantimicag.2018.09.001. Epub 2018 Sep 19.

PMID:
30240837
14.

Changes in bacterial hospital epidemiology.

Morosini MI, Cantón R.

Rev Esp Quimioter. 2018 Sep;31 Suppl 1:23-26. Review.

15.

First Report of an OXA-48- and CTX-M-213-Producing Kluyvera Species Clone Recovered from Patients Admitted in a University Hospital in Madrid, Spain.

Hernández-García M, León-Sampedro R, Pérez-Viso B, Morosini MI, López-Fresneña N, Díaz-Agero C, Coque TM, Ruiz-Garbajosa P, Cantón R.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01238-18. doi: 10.1128/AAC.01238-18. Print 2018 Nov.

PMID:
30181367
16.

MIC-based dose adjustment: facts and fables-authors' response.

Mouton JW, Muller AE, Canton R, G Giske C, Kahlmeter G, Turnidge J.

J Antimicrob Chemother. 2018 Sep 1;73(9):2585-2586. doi: 10.1093/jac/dky195. No abstract available.

PMID:
30137389
17.

Emergence of ESBL-producing Escherichia coli ST131-C1-M27 clade colonizing patients in Europe.

Merino I, Hernández-García M, Turrientes MC, Pérez-Viso B, López-Fresneña N, Diaz-Agero C, Maechler F, Fankhauser-Rodriguez C, Kola A, Schrenzel J, Harbarth S, Bonten M, Gastmeier P, Canton R, Ruiz-Garbajosa P; R-GNOSIS Study Group .

J Antimicrob Chemother. 2018 Nov 1;73(11):2973-2980. doi: 10.1093/jac/dky296.

PMID:
30124851
18.

Performance of CHROMID® Colistin R agar, a new chromogenic medium for screening of colistin-resistant Enterobacterales.

García-Fernández S, García-Castillo M, Ruiz-Garbajosa P, Morosini MI, Bala Y, Zambardi G, Cantón R.

Diagn Microbiol Infect Dis. 2019 Jan;93(1):1-4. doi: 10.1016/j.diagmicrobio.2018.07.008. Epub 2018 Aug 7.

PMID:
30097296
19.

Characterization of carbapenemase-producing Enterobacteriaceae from colonized patients in a university hospital in Madrid, Spain, during the R-GNOSIS project depicts increased clonal diversity over time with maintenance of high-risk clones.

Hernández-García M, Pérez-Viso B, Carmen Turrientes M, Díaz-Agero C, López-Fresneña N, Bonten M, Malhotra-Kumar S, Ruiz-Garbajosa P, Cantón R.

J Antimicrob Chemother. 2018 Nov 1;73(11):3039-3043. doi: 10.1093/jac/dky284.

PMID:
30053018
20.

Multicenter Evaluation of the Xpert Carba-R Assay for Detection of Carbapenemase Genes in Gram-Negative Isolates.

Traczewski MM, Carretto E, Canton R, Moore NM; Carba-R Study Team .

J Clin Microbiol. 2018 Jul 26;56(8). pii: e00272-18. doi: 10.1128/JCM.00272-18. Print 2018 Aug.

21.

Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates.

Canton R, Morrissey I, Vila J, Tato M, García-Castillo M, López Y, Gargallo-Viola D, Zsolt I.

Future Microbiol. 2018 May 1;13:3-19. doi: 10.2217/fmb-2017-0289.

22.

A review of the antibacterial activity of ozenoxacin.

Canton R, Chouinard L, Tarragó C.

Future Microbiol. 2018 May 1;13:1-2. doi: 10.2217/fmb-2018-0069. No abstract available.

23.

Ceftazidime Is the Key Diversification and Selection Driver of VIM-Type Carbapenemases.

Martínez-García L, González-Alba JM, Baquero F, Cantón R, Galán JC.

MBio. 2018 May 8;9(3). pii: e02109-17. doi: 10.1128/mBio.02109-17.

24.

Antimicrobial susceptibility trends and evolution of isolates with extended spectrum β-lactamases among Gram-negative organisms recovered during the SMART study in Spain (2011-2015).

Cantón R, Loza E, Aznar J, Barrón-Adúriz R, Calvo J, Castillo FJ, Cercenado E, Cisterna R, González-Romo F, López-Hontangas JL, Suárez-Barrenechea AI, Tubau F, Molloy B, López-Mendoza D; SMART-Spain Working Group.

Rev Esp Quimioter. 2018 Apr;31(2):136-145. Epub 2018 Mar 12.

25.

Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy.

Mensa J, Barberán J, Soriano A, Llinares P, Marco F, Cantón R, Bou G, González Del Castillo J, Maseda E, Azanza JR, Pasquau J, García-Vidal C, Reguera JM, Sousa D, Gómez J, Montejo M, Borges M, Torres A, Alvarez-Lerma F, Salavert M, Zaragoza R, Oliver A.

Rev Esp Quimioter. 2018 Feb;31(1):78-100. Epub 2018 Feb 23. Review.

26.

Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain.

García-Castillo M, García-Fernández S, Gómez-Gil R, Pitart C, Oviaño M, Gracia-Ahufinger I, Díaz-Regañón J, Tato M, Cantón R; iCREST Study Group.

Int J Antimicrob Agents. 2018 Mar;51(3):511-515. doi: 10.1016/j.ijantimicag.2018.01.011. Epub 2018 Jan 31.

PMID:
29371104
27.

The what, when and how in performing and interpreting microbiological diagnostic tests in skin and soft tissue infections.

Navarro-San Francisco C, Ruiz-Garbajosa P, Cantón R.

Curr Opin Infect Dis. 2018 Apr;31(2):104-112. doi: 10.1097/QCO.0000000000000433.

PMID:
29337704
28.

Potential Impact of Flow Cytometry Antimicrobial Susceptibility Testing on the Clinical Management of Gram-Negative Bacteremia Using the FASTinov® Kit.

Costa-de-Oliveira S, Teixeira-Santos R, Silva AP, Pinho E, Mergulhão P, Silva-Dias A, Marques N, Martins-Oliveira I, Rodrigues AG, Paiva JA, Cantón R, Pina-Vaz C.

Front Microbiol. 2017 Dec 12;8:2455. doi: 10.3389/fmicb.2017.02455. eCollection 2017.

29.

Mutant Prevention Concentration and Mutant Selection Window of Micafungin and Anidulafungin in Clinical Candida glabrata Isolates.

Bordallo-Cardona MÁ, Marcos-Zambrano LJ, Sánchez-Carrillo C, de la Pedrosa EGG, Cantón R, Bouza E, Escribano P, Guinea J.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01982-17. doi: 10.1128/AAC.01982-17. Print 2018 Mar.

30.

Fungi in Bronchiectasis: A Concise Review.

Máiz L, Nieto R, Cantón R, Gómez G de la Pedrosa E, Martinez-García MÁ.

Int J Mol Sci. 2018 Jan 4;19(1). pii: E142. doi: 10.3390/ijms19010142. Review.

31.

Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance.

De Waele JJ, Akova M, Antonelli M, Canton R, Carlet J, De Backer D, Dimopoulos G, Garnacho-Montero J, Kesecioglu J, Lipman J, Mer M, Paiva JA, Poljak M, Roberts JA, Rodriguez Bano J, Timsit JF, Zahar JR, Bassetti M.

Intensive Care Med. 2018 Feb;44(2):189-196. doi: 10.1007/s00134-017-5036-1. Epub 2017 Dec 29.

PMID:
29288367
32.

Susceptibility testing and detection of β-lactam resistance mechanisms in Enterobacteriaceae: a multicentre national proficiency study.

Díez-Aguilar M, Conejo MC, Morosini MI, Tormo Palop N, Gimeno C, Cantón R, Pascual Á.

Int J Antimicrob Agents. 2018 Apr;51(4):612-619. doi: 10.1016/j.ijantimicag.2017.12.008. Epub 2017 Dec 21.

PMID:
29274802
33.

Low and constant micafungin concentrations may be sufficient to lead to resistance mutations in FKS2 gene of Candida glabrata.

Bordallo-Cardona MÁ, Escribano P, Marcos-Zambrano LJ, Díaz-García J, de la Pedrosa EG, Cantón R, Bouza E, Guinea J.

Med Mycol. 2018 Oct 1;56(7):903-906. doi: 10.1093/mmy/myx124.

PMID:
29228268
34.

MIC-based dose adjustment: facts and fables.

Mouton JW, Muller AE, Canton R, Giske CG, Kahlmeter G, Turnidge J.

J Antimicrob Chemother. 2018 Mar 1;73(3):564-568. doi: 10.1093/jac/dkx427.

PMID:
29216348
35.

Virulence genes and subclone status as markers of experimental virulence in a murine sepsis model among Escherichia coli sequence type 131 clinical isolates from Spain.

Merino I, Porter SB, Johnston BD, Clabots C, Shaw E, Horcajada JP, Cantón R, Ruiz-Garbajosa P, Johnson JR; ITUBRAS-GEIH group.

PLoS One. 2017 Nov 30;12(11):e0188838. doi: 10.1371/journal.pone.0188838. eCollection 2017.

36.

Spanish Guidelines on the Evaluation and Diagnosis of Bronchiectasis in Adults.

Martínez-García MÁ, Máiz L, Olveira C, Girón RM, de la Rosa D, Blanco M, Cantón R, Vendrell M, Polverino E, de Gracia J, Prados C.

Arch Bronconeumol. 2018 Feb;54(2):79-87. doi: 10.1016/j.arbres.2017.07.015. Epub 2017 Nov 9. English, Spanish.

37.

Spanish Guidelines on Treatment of Bronchiectasis in Adults.

Martínez-García MÁ, Máiz L, Olveira C, Girón RM, de la Rosa D, Blanco M, Cantón R, Vendrell M, Polverino E, de Gracia J, Prados C.

Arch Bronconeumol. 2018 Feb;54(2):88-98. doi: 10.1016/j.arbres.2017.07.016. Epub 2017 Nov 9. English, Spanish.

38.

Prevalence of extended-spectrum beta-lactamase and carbapenemase-producing bloodstream isolates of Klebsiella pneumoniae in a tertiary care hospital.

Abodakpi H, Chang KT, Sánchez Díaz AM, Cantón R, Lasco TM, Chan K, Sofjan AK, Tam VH.

J Chemother. 2018 Apr;30(2):115-119. doi: 10.1080/1120009X.2017.1399233. Epub 2017 Nov 10.

PMID:
29125052
39.

Organization of Patient Management and Fungal Epidemiology in Cystic Fibrosis.

Schwarz C, Bouchara JP, Buzina W, Chrenkova V, Dmeńska H, de la Pedrosa EGG, Cantón R, Fiscarelli E, Le Govic Y, Kondori N, Matos T, Romanowska E, Ziesing S, Sedlacek L.

Mycopathologia. 2018 Feb;183(1):7-19. doi: 10.1007/s11046-017-0205-x. Epub 2017 Nov 3.

PMID:
29098487
40.

Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.

Díez-Aguilar M, Morosini MI, Köksal E, Oliver A, Ekkelenkamp M, Cantón R.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01650-17. doi: 10.1128/AAC.01650-17. Print 2018 Jan.

41.

Economic impact of rapid diagnostic methods in Clinical Microbiology: Price of the test or overall clinical impact.

Cantón R, Gómez G de la Pedrosa E.

Enferm Infecc Microbiol Clin. 2017 Dec;35(10):659-666. doi: 10.1016/j.eimc.2017.09.005. Epub 2017 Oct 14. English, Spanish.

PMID:
29033026
42.

Individual Patterns of Complexity in Cystic Fibrosis Lung Microbiota, Including Predator Bacteria, over a 1-Year Period.

de Dios Caballero J, Vida R, Cobo M, Máiz L, Suárez L, Galeano J, Baquero F, Cantón R, Del Campo R.

MBio. 2017 Sep 26;8(5). pii: e00959-17. doi: 10.1128/mBio.00959-17.

43.

Interplay among Resistance Profiles, High-Risk Clones, and Virulence in the Caenorhabditis elegans Pseudomonas aeruginosa Infection Model.

Sánchez-Diener I, Zamorano L, López-Causapé C, Cabot G, Mulet X, Peña C, Del Campo R, Cantón R, Doménech-Sánchez A, Martínez-Martínez L, Arcos SC, Navas A, Oliver A.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01586-17. doi: 10.1128/AAC.01586-17. Print 2017 Dec.

44.

European Respiratory Society guidelines for the management of adult bronchiectasis.

Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, Murris M, Cantón R, Torres A, Dimakou K, De Soyza A, Hill AT, Haworth CS, Vendrell M, Ringshausen FC, Subotic D, Wilson R, Vilaró J, Stallberg B, Welte T, Rohde G, Blasi F, Elborn S, Almagro M, Timothy A, Ruddy T, Tonia T, Rigau D, Chalmers JD.

Eur Respir J. 2017 Sep 9;50(3). pii: 1700629. doi: 10.1183/13993003.00629-2017. Print 2017 Sep.

PMID:
28889110
45.

Epidemiology of antibiotic resistance in Pseudomonas aeruginosa. Implications for empiric and definitive therapy.

Ruiz-Garbajosa P, Cantón R.

Rev Esp Quimioter. 2017 Sep;30 Suppl 1:8-12. Review.

46.

Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations.

Aguado JM, Silva JT, Fernández-Ruiz M, Cordero E, Fortún J, Gudiol C, Martínez-Martínez L, Vidal E, Almenar L, Almirante B, Cantón R, Carratalá J, Caston JJ, Cercenado E, Cervera C, Cisneros JM, Crespo-Leiro MG, Cuervas-Mons V, Elizalde-Fernández J, Fariñas MC, Gavaldà J, Goyanes MJ, Gutiérrez-Gutiérrez B, Hernández D, Len O, López-Andujar R, López-Medrano F, Martín-Dávila P, Montejo M, Moreno A, Oliver A, Pascual A, Pérez-Nadales E, Román-Broto A, San-Juan R, Serón D, Solé-Jover A, Valerio M, Muñoz P, Torre-Cisneros J; Spanish Society of Transplantation (SET); Group for Study of Infection in Transplantation of the Spanish Society of Infectious Diseases and Clinical Microbiology (GESITRA-SEIMC); Spanish Network for Research in Infectious Diseases (REIPI) (RD16/0016).

Transplant Rev (Orlando). 2018 Jan;32(1):36-57. doi: 10.1016/j.trre.2017.07.001. Epub 2017 Jul 26. Review.

PMID:
28811074
47.

Antibiotic resistance and population structure of cystic fibrosis Pseudomonas aeruginosa isolates from a Spanish multi-centre study.

López-Causapé C, de Dios-Caballero J, Cobo M, Escribano A, Asensio Ó, Oliver A, Del Campo R, Cantón R, Solé A, Cortell I, Asensio O, García G, Martínez MT, Cols M, Salcedo A, Vázquez C, Baranda F, Girón R, Quintana E, Delgado I, de Miguel MÁ, García M, Oliva C, Prados MC, Barrio MI, Pastor MD, Olveira C, de Gracia J, Álvarez A, Escribano A, Castillo S, Figuerola J, Togores B, Oliver A, López C, de Dios Caballero J, Tato M, Máiz L, Suárez L, Cantón R.

Int J Antimicrob Agents. 2017 Sep;50(3):334-341. doi: 10.1016/j.ijantimicag.2017.03.034. Epub 2017 Jul 20.

PMID:
28735882
48.

Evolution of the Pseudomonas aeruginosa mutational resistome in an international Cystic Fibrosis clone.

López-Causapé C, Sommer LM, Cabot G, Rubio R, Ocampo-Sosa AA, Johansen HK, Figuerola J, Cantón R, Kidd TJ, Molin S, Oliver A.

Sci Rep. 2017 Jul 17;7(1):5555. doi: 10.1038/s41598-017-05621-5.

49.

Insights into a Novel blaKPC-2-Encoding IncP-6 Plasmid Reveal Carbapenem-Resistance Circulation in Several Enterobacteriaceae Species from Wastewater and a Hospital Source in Spain.

Yao Y, Lazaro-Perona F, Falgenhauer L, Valverde A, Imirzalioglu C, Dominguez L, Cantón R, Mingorance J, Chakraborty T.

Front Microbiol. 2017 Jun 28;8:1143. doi: 10.3389/fmicb.2017.01143. eCollection 2017.

50.

Serum levels of decabromodiphenyl ether (BDE-209) in women from different European countries and possible relationships with lifestyle and diet.

van den Berg M, Houba R, Leslie HA, Canton RF, Thomsen C, Becher G, Alvarez-Pedrerol M, Deu JS, Steiner M, van Tongeren M, Brunekreef B, de Boer J.

Environ Int. 2017 Oct;107:16-24. doi: 10.1016/j.envint.2017.06.014. Epub 2017 Jun 23.

PMID:
28651164

Supplemental Content

Loading ...
Support Center